Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
This new article publication from Acta Pharmaceutica Sinica B, discusses how disrupting calcium homeostasis and glycometabolism in engineered lipid-based pharmaceuticals propel cancer immunogenic death.
Homeostasis and energy and substance metabolism reprogramming shape various tumour microenvironment to sustain cancer stemness, self-plasticity and treatment resistance.
Aiming at them, a lipid-based pharmaceutical loaded with CaO2 and glucose oxidase (GOx) (LipoCaO2/GOx, LCG) has been obtained to disrupt calcium homeostasis and interfere with glycometabolism.
The loaded GOx can decompose glucose into H2O2 and gluconic acid, thus competing with anaerobic glycolysis to hamper lactic acid (LA) secretion.
The obtained gluconic acid further deprives CaO2 to produce H2O2 and release Ca2+, disrupting Ca2+ homeostasis, which synergises with GOx-mediated glycometabolism interference to deplete glutathione (GSH) and yield reactive oxygen species (ROS).
Systematical experiments reveal that these sequential multifaceted events unlocked by Ca2+ homeostasis disruption and glycometabolism interference, ROS production and LA inhibition, successfully enhance cancer immunogenic deaths of breast cancer cells, hamper regulatory T cells (Tregs) infiltration and promote CD8+ T recruitment, which receives a considerably-inhibited outcome against breast cancer progression.
Collectively, this calcium homeostasis disruption glycometabolism interference strategy effectively combines ion interference therapy with starvation therapy to eventually evoke an effective anti-tumour immune environment, which represents in the field of biomedical research.
Keywords: Calcium homeostasis disruption; Glycometabolism interference; Immunogenic cell death; Oxidative stress; Lactic acid; Engineered lipids; Starvation therapy; Cancer plasticity
Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383524004751-ga1_lrg.jpg
Engineered lipid-based pharmaceuticals unlocked sequential multifaceted events to disrupt calcium homeostasis and glucose metabolism, eventually augmenting immunogenic cell death of breast cancer to repress breast cancer progression.
Source: Compuscript Ltd
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.